Relationship between HLA-DP supertype and survival in childhood acute lymphoblastic leukaemia: Evidence for selective loss of immunological control of residual disease?

British Journal of Haematology

Volumn 145, Issue 1, 2009, Pages 87-95

  Taylor, G Malcolm ^a   Richards, Sue ^e   Wade, Rachel ^e   Hussain, Adiba ^a   Simpson, Jill ^a   Hill, Frank ^b   Mitchell, Chris ^c   Eden, Tim ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Acute lymphoblastic leukaemia; DP supertypes; HLA DPB1; Paediatric; Prognosis

Indexed keywords

HLA DP ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVENT FREE SURVIVAL; FEMALE; HETEROZYGOTE; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; T LYMPHOCYTE; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DP ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; METHOTREXATE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 61849174824     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07571.x     Document Type: Article

References (50)

1. Alessandri, A.J., Reid, G.S.D., Bader, S.A., Massing, B.G., Sorensen, P.H. Schultz, K.R. (2002) ETV6 (TEL)-AML1 pre-B acute lympblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. British Journal of Haematology, 116, 266 272.
2. Begovich, A.B., Moonsamy, P.V., Mack, S.J., Barcellos, L.F., Steiner, L.L., Grams, S., Suraj-Baker, V., Hollenbach, J., Trachtenberg, E., Louie, L., Zimmerman, P., Hill, A.V.S., Stoneking, M., Sasazuki, T., Konenkov, V.I., Sartakova, M.L., Titanji, V.P.K., Rickards, O. Klitz, W. (2001) Genetic variability & linkage disequilibrium within the DP-region:analysis of 15 different populations. Tissue Antigens, 57, 424 439.
3. Bostrom, B.C., Sensel, M.R., Sather, H.N., Gaynon, P.S., La, M.K., Johnston, K., Erdmann, G.R., Gold, S., Heerema, N.A., Hutchinson, R.J., Provisor, A.J. Trigg, M.E. (2003) Dexamethasone verus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood, 101, 3809 3817.
4. Cardoso, A.A., Schultze, J.L., Boussiotis, V.A., Freeman, G.J., Seamon, M.J., Laszlo, S., Billet, A., Sallan, S.E., Gribben, J.G. Nadler, L.M. (1996) Pre-B acute lymphoblastic leukemia cells may induce T cell anergy to alloantigen. Blood, 88, 41 48.
5. Casper, J.T., Marrari, M., Piaskowski, V., Lauer, S.J. Duquesnoy, R.J. (1982) Association between HLA-D region antigens and disease-free survival in childhood non-T, non-B acute lymphocytic leukaemia. Blood, 60, 698 702.
6. Chamuleau, M.E.D., Souwer, Y., Van Ham, S.M., Zevenbergen, A., Westers, T.M., Berkhof, J., Meijer, C.J.L.M., Van de Loosdrecht, A.A. Ossenkoppele, G.J. (2004) Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Research, 64, 5546 5550.
7. Cheok, M.H. Evans, W.E. (2006) Acute lymphoblastic leukaemia: a model for the pharmacogenetics of cancer therapy. Nature Reviews. Cancer, 6, 117 129.
8. Chessells, J.M., Bailey, C., Richards, S.M. for the Medical Research Council Working Party on Childhood Leukaemia. (1995) Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet, 345, 143 148.
9. Cupps, T.R. Fauci, A.S. (1982) Corticosteroid-mediated immunoregulation in man. Immunological Reviews, 65, 133 155.
10. De Koster, H.S., Kenter, M.J.H., D'Amaro, J., Luiten, R.M., Schroeijers, W.E.M., Giphart, M.J. Termijtelen, A. (1991) Positive correlation between oligonucleotide typing and T-cell recognition of HLA-DP molecules. Immunogenetics, 34, 12 22.
11. Diaz, G., Amicosante, M., Jaraquemada, D., Butler, R.H., Guillen, M.V., Sanchez, M., Nombela, C. Arroyo, J. (2003) Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9,11,35,55, 56,69 and 84-87 in T cell allorecognition and peptide binding. International Immunology, 15, 565 576.
12. Doytchinova, I.A. Flower, D.R. (2005) In silico identification of supertypes for class II MHCs. Journal of Immunology, 174, 7085 7095.
13. Eden, O.B., Harrison, G., Richards, S., Lilleyman, J., Bailey, C.C., Chessells, J.M., Hann, I.M., Hill, F.G.H., Gibson, B.E.S. on behalf of the Medical Research Council Childhood Leukaemia Working Party. (2000) Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Leukemia, 14, 2307 2320.
14. Friedmann, A.M. Weinstein, H.J. (2000) The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. The Oncologist, 5, 321 328.
15. Galon, J., Franchimont, D., Hiroi, N., Frey, G., Boettner, A., Ehrhart-Bornstein, M., O' Shea, J.J., Chrousos, G.P. Bornstein, S.R. (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB Journal, 16, 61 71.
16. Guglielmi, C., Cordone, I., Boecklin, F., Masi, S., Valentini, T., Vegna, M.L., Ferrrari, A., Testi, A.M. Foa, R. (1997) Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications. Leukemia, 11, 1501 1507.
17. Hahn, B.H., MacDermott, R.F., Jacobs, S.B., Pletscher, L.S. Beale, M.G. (1980) Immunosuppressive effects of low doses of glucocorticoids: effects on autologous and allogeneic mixed leukocyte reactions. Journal of Immunology, 124, 2812 2817.
18. Hammer, J., Sturniolo, T. Sinigaglia, F. (1997) HLA class II peptide binding specificity and autoimmunity. Advances in Immunology, 66, 67 100.
19. Hann, I.M., Richards, S.M., Eden, O.B., Hill, F.G.H. on behalf of the Medical Research Council Childhood Leukaemia Working Party. (1998) Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom acute lympho-blastic leukaemia trial XI (MRC UKALLXI). Leukemia, 12, 1249 1255.
20. Hann, I., Vora, A., Richards, S., Hill, F., Gibson, B., Lilleyman, J., Kinsey, S., Mitchell, C. Eden, O.B. (2000) Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results for MRC UKALL XI and MRC ALL97 randomised trials. Leukemia, 14, 356 363.
21. Hann, I., Vora, A., Harrison, G., Harrison, C.J., Martineau, M., Moorman, A.V., Secker Walker, L.M., Eden, O., Hill, F., Gibson, B., Richards, S. on behalf of the UK Medical Research Council's Working Party on childhood leukaemia. (2001) Determinants of outcome after intensified therapy of acute lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. British Journal of Haematology, 113, 103 114.
22. Hill, F.G.H., Richards, S., Gibson, B., Hann, I., Lilleyman, J., Kinsey, S., Mitchell, C., Harrison, C.J., Eden, O.B. on behalf of the UK Medical Research Council Working Party of Childhood Leukaemia 2004) Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). British Journal of Haematology, 124, 33 46.
23. Ibisch, C., Gallot, G., Vivien, R., Diez, E., Jotereau, F., Garand, R. Vie, H. (1999) Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation. Bone Marrow Transplantation, 23, 1153 1159.
24. Jastaniah, W.A., Alessandri, A.J., Reid, G.S.D. Schultz, K.R. (2006) HLA-DM expression is elevated in ETV-6-AML1 translocation-positive pediatric acute lymphoblastic leukemia. Leukemia Research, 30, 487 489.
25. Kaspers, G.J., Veerman, A.J., Popp-Snijders, C., Lomecky, M., Van Zantwijk, C.H., Swinkels, L.M., Van Wering, E.R. Pieters, R. (1996) Comparison of the anti-leukemic activity in vitro of dexamethasone and prednislone in childhood acute lymphoblastic leukemia. Medical Pediatric Oncology, 27, 114 121.
26. Kersey, J.H. (1997) Fifty years of studies of the biology and therapy of childhood leukemia. Blood, 90, 4243 4251.
27. Kessler, J.H. Melief, C.J.M. (2007) Identification of T cell epitopes for cancer immunotherapy. Leukemia, 21, 1859 1874.
28. Lauten, M., Mattias, T., Stanulla, M., Beger, C., Welte, K. Schrappe, M. (2002) Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and interleukin 10 genes. Leukemia, 16, 1437 1442.
29. Mackall, C.L. (2000) T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells, 18, 10 18.
30. Madden, D.R. (1995) The three-dimensional structure of peptide-MHC complexes. Annual Review of Immunology, 13, 587 622.
31. Madsen, M., Kissmeyer-Nielsen, F., Rasmussen, P. Andersen, P. (1981) Decreased expression of HLA-DR antigens on peripheral blood B lymphocytes during glucocorticoid treatment. Tissue Antigens, 17, 195 204.
32. Mitchell, C.D., Richards, S.M., Kinsey, S.E., Lilleyman, J.E., Vora, A. Eden, T.O. (2005) Benefit of dexa methasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Reseach Council ALL 97 randomised trial. British Journal of Haematology, 129, 734 745.
33. Moser, M., De Smedt, T., Sornasse, T., Tielemans, F., Chentoufi, A.A., Muraille, E., Van Mechelen, M., Urbain, J. Leo, O. (1995) Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. European Journal of Immunology, 25, 2818 2824.
34. Pan, J., Ju, D., Wang, Q., Zhang, M., Xia, D., Zhang, L., Yu, H. Cao, X. (2001) Dexamethasone inhibits the antigen presentation of dendritic cells in MHC class II pathway. Immunology Letters, 76, 153 161.
35. Peto, J., Eden, O.B., Lilleyman, J. Richards, S. (1986) Improvement in treatment for children with acute lymphoblastic leukaemia. The Medical Research Council UKALL Trials, 1972-84. Lancet, 327, 408 411.
36. Pui, C.-H., Raimondi, S.C., Behm, F.G., Ochs, J., Furman, W.L., Bunin, N.J., Ribero, R.C., Tinsley, P.A. Mirro, J. (1986) Shifts in blast cell phenotype and karyotype at relapse of childhood acute lymphoblastic leukemia. Blood, 68, 1306 1310.
37. Pui, C.-H., Relling, M.V. Downing, J.R. (2004) Acute lymphoblastic leukemia. New England Journal of Medicine, 350, 1535 1548.
38. Richards, S., Burrett, J., Hann, I., Chessells, J., Hill, F., Bailey, C. for the Medical Research Council Working Party on Childhood Leukaemia. (1998) Improved survival after early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Leukemia, 12, 1031 1036.
39. Rozkova, D., Horvath, R., Bartunkova, J. Spisek, R. (2006) Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clinical Immunology, 120, 260 271.
40. Rutten, C.E., Van Luxemberg-Heijs, S.A.P., Griffioen, M., Marijt, E.W.A., Jedema, I., Heemskerk, M.H.M., Posthuma, E.F.M., Willemze, R. Falkenburg, J.H.F. (2008) HLA-DP as specific target for cellular immunotherapy in HLA class-II expressing B-cell leukaemia. Leukemia, 22, 1387 1394.
41. Schrappe, M., Camitta, B., Pui, C.-H., on behalf of Eden, T., Gaynon, P., Gustafsson, G., Janka-Schaub, G.E., Kamps, W., Masera, G., Sallan, S., Tsuchida, M. Vilmer, E. (2000) Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia, 14, 2193 2194.
42. Stannulla, M., Cario, G., Meissner, B., Schrauder, A., Möricke, A., Riehm, H. Schrappe, M. (2007) Integrating molecular information into treatment of childhood acute lymphoblastic leukemia - a perspective from the BFM study. Blood Cells, Molecules, and Diseases, 39, 160 163.
43. Steinherz, P.G., Gaynon, P.S., Breneman, J.C., Cherlow, J.M., Grossman, N.J., Kersey, J.H., Johnstone, H.S., Sather, H.N., Trigg, M.E., Chappell, R., Hammond, D. Bleyer, W.A. (1996) Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance early marrow response: report from the Children's Cancer Group. Journal of Clinical Oncology, 14, 389 398.
44. Takeuchi, S., Takeuchi, N., Tsukasaki, K., Bartram, C.R., Zimmermann, M., Schrappe, M., Taguchi, H. Koeffler, H.P. (2002) Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 119, 985 987.
45. Taylor, G.M., Dearden, S., Ravetto, P., Ayres, M., Watson, P., Hussain, A., Greaves, M., Alexander, F., Eden, O.B. UKCCS Investigators 2002) Genetic susceptibility to childhood common acute paediatric lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. Human Molecular Genetics, 11, 1585 1597.
46. Taylor, M., Harrison, C., Eden, T., Birch, J., Greaves, M., Lightfoot, T. Hussain, A. (2008a) HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention. Cancer Immunology and Immunotherapy, 57, 53 61.
47. Taylor, G.M., Hussain, A., Lightfoot, T.J., Birch, J.M., Eden, T.O.B., Greaves, M.F. on behalf of UKCCS Investigators 2008b) HLA-associated susceptibility to childhood B cell precursor ALL: definition and role of HLA-DPB1-supertypes. British Journal of Cancer, 98, 1125 1131.
48. UK Childhood Cancer Study Investigators 2000) The United Kingdom Childhood Cancer Study: objectives, materials and methods. British Journal of Cancer, 82, 1073 1102.
49. Wilckens, T. De Rijk, R. (1997) Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunology Today, 18, 418 424.
50. Yun, C., Senju, S., Fujita, H., Tsuji, Y., Irie, A., Matsushita, S. Nishimura, Y. (1999) Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T cell clone reacting with to TEL/AML1 fusion protein. Tissue Antigens, 54, 153 161.